PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
AXSM vs. INZY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between AXSM and INZY is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

AXSM vs. INZY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Axsome Therapeutics, Inc. (AXSM) and Inozyme Pharma, Inc. (INZY). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%AugustSeptemberOctoberNovemberDecember2025
14.14%
-74.05%
AXSM
INZY

Key characteristics

Sharpe Ratio

AXSM:

0.23

INZY:

-0.94

Sortino Ratio

AXSM:

0.66

INZY:

-1.50

Omega Ratio

AXSM:

1.08

INZY:

0.81

Calmar Ratio

AXSM:

0.26

INZY:

-0.70

Martin Ratio

AXSM:

0.62

INZY:

-1.73

Ulcer Index

AXSM:

16.05%

INZY:

38.82%

Daily Std Dev

AXSM:

43.03%

INZY:

71.63%

Max Drawdown

AXSM:

-86.65%

INZY:

-96.52%

Current Drawdown

AXSM:

-11.76%

INZY:

-95.43%

Fundamentals

Market Cap

AXSM:

$4.54B

INZY:

$88.65M

EPS

AXSM:

-$6.58

INZY:

-$1.55

Total Revenue (TTM)

AXSM:

$266.93M

INZY:

$0.00

Gross Profit (TTM)

AXSM:

$242.31M

INZY:

-$565.00K

EBITDA (TTM)

AXSM:

-$204.05M

INZY:

-$70.25M

Returns By Period

In the year-to-date period, AXSM achieves a 10.80% return, which is significantly higher than INZY's -50.18% return.


AXSM

YTD

10.80%

1M

4.54%

6M

11.95%

1Y

10.36%

5Y*

0.75%

10Y*

N/A

INZY

YTD

-50.18%

1M

-54.30%

6M

-75.96%

1Y

-66.67%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

AXSM vs. INZY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AXSM
The Risk-Adjusted Performance Rank of AXSM is 5656
Overall Rank
The Sharpe Ratio Rank of AXSM is 5858
Sharpe Ratio Rank
The Sortino Ratio Rank of AXSM is 5353
Sortino Ratio Rank
The Omega Ratio Rank of AXSM is 5151
Omega Ratio Rank
The Calmar Ratio Rank of AXSM is 6161
Calmar Ratio Rank
The Martin Ratio Rank of AXSM is 5656
Martin Ratio Rank

INZY
The Risk-Adjusted Performance Rank of INZY is 66
Overall Rank
The Sharpe Ratio Rank of INZY is 66
Sharpe Ratio Rank
The Sortino Ratio Rank of INZY is 55
Sortino Ratio Rank
The Omega Ratio Rank of INZY is 66
Omega Ratio Rank
The Calmar Ratio Rank of INZY is 88
Calmar Ratio Rank
The Martin Ratio Rank of INZY is 33
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

AXSM vs. INZY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Axsome Therapeutics, Inc. (AXSM) and Inozyme Pharma, Inc. (INZY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for AXSM, currently valued at 0.23, compared to the broader market-2.000.002.000.23-0.94
The chart of Sortino ratio for AXSM, currently valued at 0.66, compared to the broader market-4.00-2.000.002.004.000.66-1.50
The chart of Omega ratio for AXSM, currently valued at 1.08, compared to the broader market0.501.001.502.001.080.81
The chart of Calmar ratio for AXSM, currently valued at 0.31, compared to the broader market0.002.004.006.000.31-0.70
The chart of Martin ratio for AXSM, currently valued at 0.62, compared to the broader market-30.00-20.00-10.000.0010.0020.000.62-1.73
AXSM
INZY

The current AXSM Sharpe Ratio is 0.23, which is higher than the INZY Sharpe Ratio of -0.94. The chart below compares the historical Sharpe Ratios of AXSM and INZY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
0.23
-0.94
AXSM
INZY

Dividends

AXSM vs. INZY - Dividend Comparison

Neither AXSM nor INZY has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AXSM vs. INZY - Drawdown Comparison

The maximum AXSM drawdown since its inception was -86.65%, smaller than the maximum INZY drawdown of -96.52%. Use the drawdown chart below to compare losses from any high point for AXSM and INZY. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-6.71%
-95.43%
AXSM
INZY

Volatility

AXSM vs. INZY - Volatility Comparison

The current volatility for Axsome Therapeutics, Inc. (AXSM) is 19.39%, while Inozyme Pharma, Inc. (INZY) has a volatility of 40.91%. This indicates that AXSM experiences smaller price fluctuations and is considered to be less risky than INZY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
19.39%
40.91%
AXSM
INZY

Financials

AXSM vs. INZY - Financials Comparison

This section allows you to compare key financial metrics between Axsome Therapeutics, Inc. and Inozyme Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab